HPV (HUMAN PAPILLOMAVIRUS)

Cervical cancer, caused by HPV infection, is estimated to affect approximately 500,000 women each year

2nd

most frequent cancer in women

According to the World Health Organization (WHO), cervical cancer is the second most frequent cancer in women in the world.

3rd

greatest cause of death

According to the World Health Organization (WHO), cervical cancer is the third greatest cause of death from cancer in women

270,000

Estimated deaths per year.

Cervical cancer is estimated to cause 270,000 deaths every year, with more than 85% of the deaths occurring in developing countries.

 

The Agilvax Solution for HPV

Agilvax is developing AX03 as a lead vaccine candidate for HPV prevention. AX03 has shown protection in vivo against all eleven HPV genotypes tested. It has also been shown to be effective against HPV causing genital and cutaneous warts. AX03 is composed of a single VLP with a highly conserved L2 peptide. The vaccine is cost effective due to production in a bacterial expression system. Agilvax is ready to initiate GMP manufacturing to conduct toxicology studies and phase I proof of concept clinical testing. AX03 represents the validation of the proprietary VLP technology platform and represents a significant licensing opportunity for the company.